Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
2.

Progress in measurement instruments for acute and chronic gout studies.

Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR.

J Rheumatol. 2009 Oct;36(10):2346-55. doi: 10.3899/jrheum.090371.

PMID:
19820224
3.

Outcome domains for studies of acute and chronic gout.

Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh J, Evans R, Waltrip RW, Diaz-Torne C, MacDonald P, McQueen F, Perez-Ruiz F.

J Rheumatol. 2009 Oct;36(10):2342-5. doi: 10.3899/jrheum.090370.

PMID:
19820223
4.

Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping.

Taylor WJ, Shewchuk R, Saag KG, Schumacher HR Jr, Singh JA, Grainger R, Edwards NL, Bardin T, Waltrip RW, Simon LS, Burgos-Vargas R.

Arthritis Rheum. 2009 Apr 15;61(4):535-43. doi: 10.1002/art.24166.

5.

Resolution of gouty tophi after twelve weeks of pegloticase treatment.

Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW 2nd.

Arthritis Rheum. 2008 Nov;58(11):3632-4. doi: 10.1002/art.23993. No abstract available.

6.

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators.

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

7.

Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.

Yue CS, Huang W, Alton M, Maroli AN, Waltrip RW, Wright D, Marco MD.

J Clin Pharmacol. 2008 Jun;48(6):708-18. doi: 10.1177/0091270008317589. Epub 2008 Apr 16.

PMID:
18420531
8.

Synthetic peptide-based electrochemiluminescence immunoassay for anti-Borna disease virus p40 and p24 antibodies in rat and horse serum.

Yamaguchi K, Sawada T, Yamane S, Haga S, Ikeda K, Igata-Yi R, Yoshiki K, Matsuoka M, Okabe H, Horii Y, Nawa Y, Waltrip RW 2nd, Carbone KM.

Ann Clin Biochem. 2001 Jul;38(Pt 4):348-55.

PMID:
11471876
9.

Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay.

Yamaguchi K, Sawada T, Naraki T, Igata-Yi R, Shiraki H, Horii Y, Ishii T, Ikeda K, Asou N, Okabe H, Mochizuki M, Takahashi K, Yamada S, Kubo K, Yashiki S, Waltrip RW 2nd, Carbone KM.

Clin Diagn Lab Immunol. 1999 Sep;6(5):696-700.

10.

Clinical, serologic, and histopathologic characterization of experimental Borna disease in ponies.

Katz JB, Alstad D, Jenny AL, Carbone KM, Rubin SA, Waltrip RW 2nd.

J Vet Diagn Invest. 1998 Oct;10(4):338-43.

PMID:
9786521
11.

Borna disease virus antibodies and the deficit syndrome of schizophrenia.

Waltrip RW 2nd, Buchanan RW, Carpenter WT Jr, Kirkpatrick B, Summerfelt A, Breier A, Rubin SA, Carbone KM.

Schizophr Res. 1997 Feb 28;23(3):253-7.

PMID:
9075304
12.

Hematologic consequences of Borna disease virus infection of rat bone marrow and thymus stromal cells.

Rubin SA, Sierra-Honigmann AM, Lederman HM, Waltrip RW 2nd, Eiden JJ, Carbone KM.

Blood. 1995 May 15;85(10):2762-9.

PMID:
7742537
13.

Borna disease virus and schizophrenia.

Waltrip RW 2nd, Buchanan RW, Summerfelt A, Breier A, Carpenter WT Jr, Bryant NL, Rubin SA, Carbone KM.

Psychiatry Res. 1995 Jan 31;56(1):33-44.

PMID:
7792340
14.
15.

The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy.

Breier A, Buchanan RW, Waltrip RW 2nd, Listwak S, Holmes C, Goldstein DS.

Neuropsychopharmacology. 1994 Feb;10(1):1-7.

16.

Borna disease virus in mice: host-specific differences in disease expression.

Rubin SA, Waltrip RW 2nd, Bautista JR, Carbone KM.

J Virol. 1993 Jan;67(1):548-52.

17.

Borna disease: association with a maturation defect in the cellular immune response.

Carbone KM, Park SW, Rubin SA, Waltrip RW 2nd, Vogelsang GB.

J Virol. 1991 Nov;65(11):6154-64.

18.

Postpsychotic depression.

McGlashan TH, Waltrip RW 2nd.

Am J Psychiatry. 1991 Apr;148(4):545-7. No abstract available.

PMID:
2006706
19.

Carbamazepine maintenance treatment in outpatient schizophrenics.

Carpenter WT Jr, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan RW, Waltrip RW, Breier A.

Arch Gen Psychiatry. 1991 Jan;48(1):69-72.

PMID:
1670617
20.

Immunopathology and viral reactivation. A general theory of schizophrenia.

Waltrip RW 2nd, Carrigan DR, Carpenter WT Jr.

J Nerv Ment Dis. 1990 Dec;178(12):729-38. Review.

PMID:
2246646
21.

Rating affective flattening from videotaped interviews.

Waltrip RW 2nd, Strauss ME, Summerfelt A, Heinrichs D, Kirkpatrick B, Jauch D, Oltmanns TF.

Psychiatry Res. 1989 Feb;27(2):199-205.

PMID:
2710865
22.

Diazepam treatment of early symptoms of schizophrenic relapse.

Kirkpatrick B, Buchanan RW, Waltrip RW 2nd, Jauch D, Carpenter WT Jr.

J Nerv Ment Dis. 1989 Jan;177(1):52-3.

PMID:
2642535
23.

Desipramine-associated hepatitis.

Price LH, Nelson JC, Waltrip RW.

J Clin Psychopharmacol. 1983 Aug;3(4):243-6. No abstract available.

PMID:
6886037

Supplemental Content

Loading ...
Support Center